drugset / Trial / NCT06159062
A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this intervention research is to learn about the safety and tolerability of 162 with a single ascending dose in subjects with chronic hepatitis B virus (HBV) infection.
Timeline
- Start
- 2024-06-03
- Primary completion
- 2024-07-09
- Completion
- 2024-07-09
Outcome
Outcome not reported
Stopped (Enrollment): “Enrollment difficulty”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 162 | Monoclonal antibody | 50 mg | — |
| Subject | 162 | Monoclonal antibody | 75 mg | — |
| Subject | 162 | Monoclonal antibody | 100 mg | — |